Navigation Links
Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
Date:10/29/2009

CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that Novartis Pharma AG has decided not to exercise its option to license IDX184, a novel liver-targeted prodrug of 2'-methyl guanosine nucleotide, for the treatment of HCV. As a result, Idenix retains the worldwide rights to develop, commercialize and license IDX184 without any further obligation to Novartis.

"As we continue to develop IDX184, we look forward to seeking a partner that will assist us in maximizing the value of this asset," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix.

About IDX184

IDX184 is a novel, liver-targeted 2'-methyl guanosine nucleotide prodrug, which includes Idenix's proprietary liver-targeting technology. This technology enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, potentially maximizing drug efficacy and limiting systemic side effects with low, once-daily dosing.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to www.idenix.com.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
4. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
5. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
6. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
7. Idenix Pharmaceuticals Reports First Quarter Financial Results
8. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
9. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
10. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
11. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ... "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services ... Global Version" report to their offering. ... of molecular diagnostics and pharmacogenics hold the promise ... that is moving out of the national and ...
(Date:5/5/2015)... 2015 Exotic Automation & ... the launch of http://www.cng.exoticautomation.com , an ecommerce ... convenient way to purchase genuine OEM replacement CNG, ... , The new website provides owners of fleets ... access to high performance products for their vehicle ...
(Date:5/4/2015)... , May 4, 2015 Many of ... But for certain infants with rare, inherited mutations ... stark consequences of their impaired immune responses. ... have identified an important role for calcium signaling ... Mycobacterium tuberculosis, the bacterium causing tuberculosis (TB). ...
(Date:5/4/2015)... 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) announced today ... 20-F for the fiscal year ended December 31, 2014 ... annual report on Form 20-F contains information regarding its ... area of cancer immune checkpoints. This project aims to ... and binding in targeting certain identified immune checkpoints. The ...
Breaking Biology Technology:Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2Exotic Automation & Supply Launches Ecommerce Website 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2
... for healthcare applications, Polymer Science perfects its adhesive ... will introduce a new line of silicone gel ... 10-12 in Anaheim, California. To meet the ... contact applications, Polymer Science has developed three new ...
... /PRNewswire-FirstCall/ - BioSyntech, Inc. (TSX: BSY), a biotechnology ... announced that it has completed enrolment for the ... BST-CarGel(R). The Company achieved its planned objective of ... "We are grateful to the distinguished group of ...
... Cephalon, Inc .,(Nasdaq: CEPH ) today announced ... rights to Lupuzor(TM), an investigational medication for the,treatment of ... the ImmuPharma Phase IIb study. Cephalon will assume all ... of,the product. , ImmuPharma PLC ...
Cached Biology Technology:Polymer Science Releases New Silicone Gel Adhesive Products for MD&M West 2BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device 2BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device 3Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 2Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 3Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 4Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 5
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... and Voice Biometrics - Global Strategic Business Report" report to ... Face and Voice Biometrics in US$ Thousands by the following Segments: ... for the US, Canada , Japan ... , Middle East & Africa ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... can lead to life-threatening bleeding episodes is misdiagnosed in ... a new international research project led by a Queen,s ... the treatment decision," says Maha Othman, a professor in ... the three-year research project on the rare platelet type ...
... the Clark,s nutcracker in late summer and early fall may ... in most of its range, scientists have found. ... Science Findings , a monthly publication of the U.S. Forest ... the success of whitebark pine restoration may be linked to ...
... DC The Society for Neuroscience (SfN) has ... to create and maintain BrainFacts.org , a unique ... progress and promise of brain research. With joint founding ... SfN will launch the Web site in late spring ...
Cached Biology News:Conservation of whitebark pine may hinge on preservation of ponderosa 2Conservation of whitebark pine may hinge on preservation of ponderosa 3Society for Neuroscience awarded $1.53 million to create BrainFacts.org 2Society for Neuroscience awarded $1.53 million to create BrainFacts.org 3
... ALDEFLUOR Stem Cell ... technology comprises a substrate ... dehydrogenase (ALDH) that is ... viable stem cells, making ...
... LED produces output at 470 nm; includes interface ... S2000 or installed into rack or desktop boxes ... Source is an LED that produces either pulsed ... blue region -- for fluorescence measurements. The source ...
... LTQ XL extends the MSn performance of ... new tools to generate extensive structural information ... applications. , Multiple dissociation techniques (PQD, ... and unpredicted metabolites , Fast polarity switching ...
Request Info...
Biology Products: